Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18AA-VII is a standardized intravenous compound amino acid solution containing 18 essential and non-essential amino acids. It is primarily utilized in parenteral nutrition to provide a balanced nitrogen source for patients with impaired gastrointestinal function or those in hypermetabolic states, such as critical illness. The formulation is designed to maintain nitrogen balance, promote protein synthesis, and prevent the breakdown of endogenous proteins. In clinical practice, particularly in China where the 18AA-VII nomenclature is standard, it is used to support recovery in surgical patients and those in intensive care units (ICU) by meeting increased metabolic demands. The specific VII designation refers to a formulation ratio optimized for general nutritional support in patients with normal organ function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound amino acid injection (18AA-VII).